Related Experiment Video

Updated: Jun 25, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Evaluation of live attenuated S79 mumps vaccine effectiveness in mumps outbreaks: a matched case-control study

Chuan-xi Fu1, Jun Nie, Jian-hua Liang

  • 1Guangzhou Center of Disease Control and Prevention, Guangzhou, Guangdong 510080, China.

Chinese Medical Journal
|February 25, 2009
PubMed
Abstract

Insights

The live attenuated S(79) mumps vaccine demonstrated significant effectiveness in preventing clinical mumps outbreaks. One dose provided 80.4% protection, highlighting its value in pediatric populations.

Area of Science:

  • Virology
  • Immunology
  • Public Health

Background:

  • Mumps virus is a significant cause of illness in children and young adults.
  • The S(79) strain of live attenuated mumps vaccine has been available in China since 1990.
  • Assessing vaccine effectiveness during outbreaks is crucial for public health strategies.

Purpose of the Study:

  • To evaluate the effectiveness of the live attenuated S(79) mumps vaccine.
  • To determine vaccine effectiveness against clinical mumps during school outbreaks.

Main Methods:

  • Case-control study design during mumps outbreaks in Guangzhou (2004-2005).
  • Cases and controls were matched by gender, age, and classroom.
  • Vaccination status was verified through the Children's EPI Administrative Computerized System.
  • Vaccine effectiveness (VE) calculated for 1 or 2 doses with 95% confidence intervals (CI).

Main Results:

  • 194 cases and 194 controls were analyzed.
  • One dose of S(79) mumps vaccine showed 80.4% effectiveness (95% CI, 60.0%-90.4%) against mumps compared to no vaccination.
  • Effectiveness was comparable in children aged 4-9 years and those over 10 years old.

Conclusions:

  • The live attenuated S(79) mumps vaccine is effective in preventing clinical mumps.
  • The vaccine plays a vital role in controlling mumps outbreaks in pediatric populations.

More Related Videos

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens09:08

Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens

Published on: September 12, 2016

Related Concept Videos

Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Vaccinations01:51

Vaccinations

Overview
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...